Discoveries in Cancer Therapy Spark Formation of New Biotech Company
Professor Brian Lichty of MIRC has teamed up with long-term collaborators Dr. John Bell (the Ottawa Hospital and the University of Ottawa), and Dr. David Stojdl (the Children's Hospital of Eastern Ontario and the University of Ottawa) to create Turnstone Biologics Inc [...]
Professor Brian Lichty of MIRC has teamed up with long-term collaborators Dr. John Bell (the Ottawa Hospital and the University of Ottawa), and Dr. David Stojdl (the Children’s Hospital of Eastern Ontario and the University of Ottawa) to create Turnstone Biologics Inc. The startup biotech company will focus on developing new cancer therapies that harness the immune system, including a oncolytic virus- and vaccine-based treatment. The investigators have already demonstated unprecedented tumor fighting capabilities of the Maraba virus in experimental models, and expect to translate their findings into improved outcomes for cancer patients. The therapy represents the first tumor-targeted oncolytic vaccine that includes a sustained anti-cancer immune response. The founding partners’ goal to accelerate commercialization and clinical translation of immune-based cancer treatments is funded by both academic and public institutions, as well as charitable foundations. Read more about Dr. Lichty and Turnstone Biologics at the McMaster Faculty of Health Science and the Hamilton Spectator.
McMaster Immunology Research Centre, ResearchRelated News
News Listing
Two Faculty of Health Sciences cancer researchers awarded Canada Research Chairs
Dept. Biochem, Dept. Surgery, Feature, Research
7 days ago
Elena Verdu appointed director of Farncombe Family Digestive Health Research Institute
Faculty & Staff, Research
7 days ago